Published

Safety, Tolerability, and Efficacy of Psilocybin in 9 Patients With Obsessive-Compulsive Disorder

No abstract availability was recorded for this entry.

Open source BibTeX RIS

Bibliographic context

Journal: Yearbook of Psychiatry and Applied Mental Health
Date: 2008-01-01
Source: OpenAlex
DOI: 10.1016/s0084-3970(08)70820-x
PubMed: Unavailable

Authors

J.C. Ballenger

Watch author

Derived topics and classifications

psilocybin OCD Pharmacology Safety Other

Citation graph

0 referenced DOIs found in stored source metadata. 1 indexed paper cite this DOI.

Open citation network

Indexed papers citing this DOI

Safety, Tolerability, and Efficacy of Psilocybin in 9 Patients With Obsessive-Compulsive Disorder2008-01-01

Related papers

Open Label, Phase 2 Study for Evaluating the Feasibility, Safety and Efficacy of Psychotherapy Assisted Psilocybin for Treatment of Severe Obsessive Compulsive Disorder (OCD) in Drug and/or Psychotherapy Resistant Patients.ClinicalTrials.gov · 2025-11-19 Evaluating the Feasibility, Clinical Effects, and Safety of Psilocybin-assisted Psychotherapy for Treatment-resistant Obsessive-compulsive Disorder: An Open-label Clinical TrialClinicalTrials.gov · 2026-07-28 Psilocybin for Treatment of Obsessive Compulsive DisorderClinicalTrials.gov · 2026-05-12 A Randomized Double-masked Dose-controlled Trial to Assess the Tolerability, Safety, Subjective Experience, and Efficacy of Repeated Administration of Three Different Doses of Psilocybin Whole Mushroom for the Treatment of Obsessive-compulsive Disorder.ClinicalTrials.gov · 2026-07-23 Computationally, Electrophysiologically, and Qualitatively Characterizing Serotonergic Psychedelics; Transdiagnostic Therapeutic and Pro-Psychotic EffectsClinicalTrials.gov · 2026-07-09 Effects of Psilocybin in Obsessive Compulsive DisorderClinicalTrials.gov · 2026-04-02 PsilOCD: Evaluating the Effects of the 5-HT2A Agonist Psilocybin on the Neurocognitive and Clinical Correlates of Compulsivity (A Pharmacological-Challenge Feasibility Study)ClinicalTrials.gov · 2024-11-06 Psilocybin for Treatment of Obsessive Compulsive DisorderClinicalTrials.gov · 2024-08-30